200,000+ products from a single source!
sales@angenechem.com
119169-78-7 | Androsta-3,5-diene-3-carboxylic acid, 17-[[(1,1-dimethylethyl)amino]carbonyl]-, (17β)-
CAS No: 119169-78-7 Catalog No: AG000I9P MDL No:MFCD00864172
Product Description
Catalog Number:
AG000I9P
Chemical Name:
Androsta-3,5-diene-3-carboxylic acid, 17-[[(1,1-dimethylethyl)amino]carbonyl]-, (17β)-
CAS Number:
119169-78-7
Molecular Formula:
C25H37NO3
Molecular Weight:
399.5662
MDL Number:
MFCD00864172
SMILES:
OC(=O)C1=CC2=CC[C@@H]3[C@@H]([C@]2(CC1)C)CC[C@]1([C@H]3CC[C@@H]1C(=O)NC(C)(C)C)C
Literature
| Title | Journal |
|---|---|
| Discovery of a novel hybrid from finasteride and epristeride as 5α-reductase inhibitor. | Bioorganic & medicinal chemistry letters 20110101 |
| Self organizing molecular field analysis on a series of human 5alpha-reductase inhibitors: unsaturated 3-carboxysteroid. | European journal of medicinal chemistry 20091201 |
| [Comparison of different drugs on the treatment of benign prostate hyperplasia]. | Zhonghua wai ke za zhi [Chinese journal of surgery] 20070715 |
| [Effect of large-dosage of 5alpha-reductase inhibitors on the spermatogenesis of male rats]. | Zhonghua nan ke xue = National journal of andrology 20050901 |
| Twelve-year follow up of a randomized prospective trial comparing bacillus Calmette-Guerin and epirubicin as adjuvant therapy in superficial bladder cancer. | International journal of urology : official journal of the Japanese Urological Association 20050501 |
| Comparative study of human steroid 5alpha-reductase isoforms in prostate and female breast skin tissues: sensitivity to inhibition by finasteride and epristeride. | Life sciences 20020531 |
| Effect of epristeride on the expression of IGF-1 and TGF-beta receptors in androgen-induced castrated rat prostate. | Experimental biology and medicine (Maywood, N.J.) 20011101 |
| Inhibition of regrowth of prostatic glandular cells by epristeride. | Acta pharmacologica Sinica 20010901 |
Related Products
Featured Products
© 2019 Angene International Limited. All rights Reserved.